Search

Search Constraints

You searched for: Author/Creator Augustson, Bradley

Search Results

2. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial. Issue 6 (June 2022)

3. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Issue 8 (August 2017)

4. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. Issue 9 (20th June 2016)

5. Considerations for pre‐transfusion immunohaematology testing in patients receiving the anti‐CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Issue 2 (7th February 2018)

6. Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. Issue 1 (December 2016)

8. Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Issue 10 (18th October 2021)

9. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Issue 1 (4th June 2022)

10. Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). (11th July 2022)